Clinical Trial

Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside

Study acronym: Emerald-NRAD
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 6, 2025 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This project's main goal is to use state-of-the-art passive sensing techniques to identify digital biomarkers that relate to bioenergetic changes in the brain due to nicotinamide riboside supplementation in those with mild cognitive impairment and mild Alzheimer's dementia.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-02-17.
Status change: Not Yet Recruiting → Recruiting 2025-11-04
Trial Details
NCT Number NCT05245903
Lead Sponsor Mclean Hospital
Collaborators: National Institute on Aging (NIA)
Conditions Alzheimer Disease, Dementia Alzheimers, Dementia, Cognitive Impairment, Mild Cognitive Impairment, Neurodegenerative Diseases, Neurocognitive Disorders, Neurocognitive Dysfunction +2 more
Enrollment 40 participants
Start Date 2022-05-31
Primary Completion 2026-05-31 (estimated)
Study Completion 2026-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-06